BioVersys reports results from Phase 2a ENABLE study for tuberculosis treatments containing AlpE
Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in p
Phase 2a ENABLE study showed early bactericidal activity in all regimens evaluated over 14 days in p